Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
667.00
Value Traded
2.47 K
Short % Float
-
Days to Cover
2.8
+2.17%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
RNLXY Catalyst Timeline
Dated clinical, regulatory and corporate events for Renalytix plc
Past FDA Catalysts and PDUFA Decisions
How RNLXY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Renalytix plc is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RNLXY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in RNLXY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RNLXY for Q2 2026. | ||||
Ownership Trends
RNLXY Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
12.4K
Shares Sold Short
+3,701.2% vs prior count
2.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
4.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RNLXY ranks across every disease it competes in
Competitive Position is a premium feature
See how RNLXY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRNLXY News
About Renalytix plc
BIOPHARMAWATCH ELITE
Trade the next RNLXY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime